Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.

Armstrong MJ, Okanoue T, Sundby Palle M, Sejling AS, Tawfik M, Roden M

Diabetes, obesity & metabolism28 Nov 2024Cited by 14 (Europe PMC)

PMID39609879PMCIDPMC11701178DOI10.1111/dom.16065PepBankPUB-39609879

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with MASLD or MASH, mean weight change at 1 year was -11.1 kg (-11.7%) with semaglutide and -0.7 kg (-0.6%) with placebo.
In plain wordsIn adults with fatty liver disease, semaglutide led to much more weight loss than placebo after one year.
Peptide
Semaglutide
Outcome
DecreaseOverall mean weight change at 1 year
Study
n = 300
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.4 mg once daily and 2.4 mg once weekly · 1 yearAs given in this study (human).
Measurements
Mean weight change
−11.1 kg
semaglutide
Mean weight change
−0.7 kg
placebo
Source sentences
Summary
The overall mean weight change was -11.1 kg (-11.7%) and -0.7 kg (-0.6%) with semaglutide and placebo, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of data from three 48-72-week randomised trials investigating the effect of semaglutide versus placebo in adults with MASLD (NCT03357380) or biopsy-confirmed MASH (NCT02970942 and NCT03987451).
Summary · context
Pooled data for semaglutide (0.4 mg once daily and 2.4 mg once weekly [n = 163]) and placebo (n = 137) were analysed at 1 year.
Report a problemFND-3960987901
02HumanRandomized controlled trialEfficacy outcome
In adults with MASLD or MASH, semaglutide-mediated weight loss did not differ significantly between people with type 2 diabetes, pre-type 2 diabetes and no diabetes (p > 0.50 for all).
In plain wordsIn adults with fatty liver disease, weight loss with semaglutide was not significantly different between people with diabetes, prediabetes and no diabetes.
Peptide
Semaglutide
Outcome
No significant changeDifference in weight loss between diabetes status subgroups
Study
n = 300
Comparator
Between diabetes-status subgroups
Outcome group
Body weight · Metabolic and weight
Studied dose
0.4 mg once daily and 2.4 mg once weekly · 1 yearAs given in this study (human).
Source sentences
Summary
Differences between groups were not statistically significant (p > 0.50 for all).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of data from three 48-72-week randomised trials investigating the effect of semaglutide versus placebo in adults with MASLD (NCT03357380) or biopsy-confirmed MASH (NCT02970942 and NCT03987451).
Summary · context
Pooled data for semaglutide (0.4 mg once daily and 2.4 mg once weekly [n = 163]) and placebo (n = 137) were analysed at 1 year.
Report a problemFND-3960987905
03HumanRandomized controlled trialOther
In adults with MASLD or MASH given semaglutide, baseline fasting plasma glucose did not correlate with weight change.
In plain wordsIn adults with fatty liver disease given semaglutide, starting blood sugar level did not predict how much weight was lost.
Peptide
Semaglutide
Outcome
No significant changeCorrelation of baseline fasting plasma glucose with weight change
Study
n = 300
Outcome group
Body weight · Metabolic and weight
Studied dose
0.4 mg once daily and 2.4 mg once weekly · 1 yearAs given in this study (human).
Source sentences
Summary
Baseline fasting plasma glucose, glycated haemoglobin, insulin levels, insulin resistance and lipids did not correlate with weight change.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of data from three 48-72-week randomised trials investigating the effect of semaglutide versus placebo in adults with MASLD (NCT03357380) or biopsy-confirmed MASH (NCT02970942 and NCT03987451).
Summary · context
Pooled data for semaglutide (0.4 mg once daily and 2.4 mg once weekly [n = 163]) and placebo (n = 137) were analysed at 1 year.
Report a problemFND-3960987906
04HumanRandomized controlled trialOther
In adults with MASLD or MASH given semaglutide, baseline glycated haemoglobin did not correlate with weight change.
In plain wordsIn adults with fatty liver disease given semaglutide, starting HbA1c did not predict how much weight was lost.
Peptide
Semaglutide
Outcome
No significant changeCorrelation of baseline HbA1c with weight change
Study
n = 300
Outcome group
Body weight · Metabolic and weight
Studied dose
0.4 mg once daily and 2.4 mg once weekly · 1 yearAs given in this study (human).
Source sentences
Summary
Baseline fasting plasma glucose, glycated haemoglobin, insulin levels, insulin resistance and lipids did not correlate with weight change.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of data from three 48-72-week randomised trials investigating the effect of semaglutide versus placebo in adults with MASLD (NCT03357380) or biopsy-confirmed MASH (NCT02970942 and NCT03987451).
Summary · context
Pooled data for semaglutide (0.4 mg once daily and 2.4 mg once weekly [n = 163]) and placebo (n = 137) were analysed at 1 year.
Report a problemFND-3960987907
05HumanRandomized controlled trialOther
In adults with MASLD or MASH given semaglutide, baseline insulin levels did not correlate with weight change.
In plain wordsIn adults with fatty liver disease given semaglutide, starting insulin levels did not predict how much weight was lost.
Peptide
Semaglutide
Outcome
No significant changeCorrelation of baseline insulin levels with weight change
Study
n = 300
Outcome group
Body weight · Metabolic and weight
Studied dose
0.4 mg once daily and 2.4 mg once weekly · 1 yearAs given in this study (human).
Source sentences
Summary
Baseline fasting plasma glucose, glycated haemoglobin, insulin levels, insulin resistance and lipids did not correlate with weight change.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of data from three 48-72-week randomised trials investigating the effect of semaglutide versus placebo in adults with MASLD (NCT03357380) or biopsy-confirmed MASH (NCT02970942 and NCT03987451).
Summary · context
Pooled data for semaglutide (0.4 mg once daily and 2.4 mg once weekly [n = 163]) and placebo (n = 137) were analysed at 1 year.
Report a problemFND-3960987908
06HumanRandomized controlled trialOther
In adults with MASLD or MASH given semaglutide, baseline insulin resistance did not correlate with weight change.
In plain wordsIn adults with fatty liver disease given semaglutide, starting insulin resistance did not predict how much weight was lost.
Peptide
Semaglutide
Outcome
No significant changeCorrelation of baseline insulin resistance with weight change
Study
n = 300
Outcome group
Body weight · Metabolic and weight
Studied dose
0.4 mg once daily and 2.4 mg once weekly · 1 yearAs given in this study (human).
Source sentences
Summary
Baseline fasting plasma glucose, glycated haemoglobin, insulin levels, insulin resistance and lipids did not correlate with weight change.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of data from three 48-72-week randomised trials investigating the effect of semaglutide versus placebo in adults with MASLD (NCT03357380) or biopsy-confirmed MASH (NCT02970942 and NCT03987451).
Summary · context
Pooled data for semaglutide (0.4 mg once daily and 2.4 mg once weekly [n = 163]) and placebo (n = 137) were analysed at 1 year.
Report a problemFND-3960987909
07HumanRandomized controlled trialOther
In adults with MASLD or MASH given semaglutide, baseline lipid levels did not correlate with weight change.
In plain wordsIn adults with fatty liver disease given semaglutide, starting blood fat levels did not predict how much weight was lost.
Peptide
Semaglutide
Outcome
No significant changeCorrelation of baseline lipids with weight change
Study
n = 300
Outcome group
Body weight · Metabolic and weight
Studied dose
0.4 mg once daily and 2.4 mg once weekly · 1 yearAs given in this study (human).
Source sentences
Summary
Baseline fasting plasma glucose, glycated haemoglobin, insulin levels, insulin resistance and lipids did not correlate with weight change.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of data from three 48-72-week randomised trials investigating the effect of semaglutide versus placebo in adults with MASLD (NCT03357380) or biopsy-confirmed MASH (NCT02970942 and NCT03987451).
Summary · context
Pooled data for semaglutide (0.4 mg once daily and 2.4 mg once weekly [n = 163]) and placebo (n = 137) were analysed at 1 year.
Report a problemFND-3960987910
08HumanRandomized controlled trialEfficacy outcome
In adults with MASLD or MASH and type 2 diabetes, semaglutide reduced weight by 10.2 kg (10.8%) more than placebo.
In plain wordsIn adults with fatty liver disease and type 2 diabetes, semaglutide led to more weight loss than placebo.
Peptide
Semaglutide
Outcome
DecreaseTreatment difference in weight change, type 2 diabetes subgroup
Study
n = 209
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.4 mg once daily and 2.4 mg once weekly · 1 yearAs given in this study (human).
Measurements
Estimated treatment difference
−10.2 kg
type 2 diabetes
Source sentences
Summary
While numerically higher for people without type 2 diabetes, estimated treatment differences with semaglutide versus placebo were similar overall for people with type 2 diabetes (-10.2 kg; -10.8%), pre-type 2 diabetes (-9.8 kg; -10.2%) and no diabetes (-11.6 kg; -13.1%).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of data from three 48-72-week randomised trials investigating the effect of semaglutide versus placebo in adults with MASLD (NCT03357380) or biopsy-confirmed MASH (NCT02970942 and NCT03987451).
Summary · context
Pooled data for semaglutide (0.4 mg once daily and 2.4 mg once weekly [n = 163]) and placebo (n = 137) were analysed at 1 year.
Report a problemFND-3960987902
09HumanRandomized controlled trialEfficacy outcome
In adults with MASLD or MASH and pre-type 2 diabetes, semaglutide reduced weight by 9.8 kg (10.2%) more than placebo.
In plain wordsIn adults with fatty liver disease and prediabetes, semaglutide led to more weight loss than placebo.
Peptide
Semaglutide
Outcome
DecreaseTreatment difference in weight change, pre-type 2 diabetes subgroup
Study
n = 51
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.4 mg once daily and 2.4 mg once weekly · 1 yearAs given in this study (human).
Measurements
Estimated treatment difference
−9.8 kg
pre-type 2 diabetes
Source sentences
Summary
While numerically higher for people without type 2 diabetes, estimated treatment differences with semaglutide versus placebo were similar overall for people with type 2 diabetes (-10.2 kg; -10.8%), pre-type 2 diabetes (-9.8 kg; -10.2%) and no diabetes (-11.6 kg; -13.1%).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of data from three 48-72-week randomised trials investigating the effect of semaglutide versus placebo in adults with MASLD (NCT03357380) or biopsy-confirmed MASH (NCT02970942 and NCT03987451).
Summary · context
Pooled data for semaglutide (0.4 mg once daily and 2.4 mg once weekly [n = 163]) and placebo (n = 137) were analysed at 1 year.
Report a problemFND-3960987903
10HumanRandomized controlled trialEfficacy outcome
In adults with MASLD or MASH and no diabetes, semaglutide reduced weight by 11.6 kg (13.1%) more than placebo.
In plain wordsIn adults with fatty liver disease and no diabetes, semaglutide led to more weight loss than placebo.
Peptide
Semaglutide
Outcome
DecreaseTreatment difference in weight change, no diabetes subgroup
Study
n = 40
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.4 mg once daily and 2.4 mg once weekly · 1 yearAs given in this study (human).
Measurements
Estimated treatment difference
−11.6 kg
no diabetes
Source sentences
Summary
While numerically higher for people without type 2 diabetes, estimated treatment differences with semaglutide versus placebo were similar overall for people with type 2 diabetes (-10.2 kg; -10.8%), pre-type 2 diabetes (-9.8 kg; -10.2%) and no diabetes (-11.6 kg; -13.1%).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of data from three 48-72-week randomised trials investigating the effect of semaglutide versus placebo in adults with MASLD (NCT03357380) or biopsy-confirmed MASH (NCT02970942 and NCT03987451).
Summary · context
Pooled data for semaglutide (0.4 mg once daily and 2.4 mg once weekly [n = 163]) and placebo (n = 137) were analysed at 1 year.
Report a problemFND-3960987904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.

Summary

Results from this study10

Version history

Subjects

Publication types

MeSH terms

Keywords